BioLineRx Ltd.
BLRX · XNASCIK 1498403fmd_0J08HMMHA7KZ3D1JBFBJKXFJ4EManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Dec 31, 2025, 20 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | 0 | 0 | 5 | 29 | 1 |
| Cost of revenue | – | – | – | – | – | 0 | 0 | 4 | 9 | 0 |
| Gross profit | – | – | – | – | – | 0 | 0 | 1 | 20 | 1 |
| Research and development | 11 | 20 | 20 | 23 | 18 | 19 | 18 | 13 | 9 | 8 |
| Selling, general and administrative | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 6 | 6 | 3 |
| Operating income | (17) | (25) | (26) | (28) | (23) | (25) | (29) | (50) | (20) | (10) |
| Interest expense | 0 | 0 | 0 | 2 | 2 | 1 | 2 | 2 | 9 | 1 |
| Income tax expense | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (16) | (24) | (23) | (25) | (30) | (27) | (25) | (61) | (9) | (2) |